The artificial lung market size has grown rapidly in recent years. It will grow from $2.58 billion in 2025 to $2.88 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to rise in incidence of acute respiratory failure cases, early adoption of heart lung machines in cardiothoracic surgery, growth in organ transplant procedure volumes, development of membrane artificial lung technology, increasing utilization of extracorporeal life support systems.
The artificial lung market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for critical care life-support devices, growing focus on portable and compact artificial lung systems, rising investment in advanced oxygenation membrane materials, expansion of applications in emergency and trauma care, increasing adoption of minimally invasive extracorporeal support solutions. Major trends in the forecast period include increasing demand for artificial lung systems in severe respiratory failure and critical care management, rising adoption of extracorporeal support devices in complex cardiac and lung transplant surgeries, growing preference for minimally invasive and temporary lung support alternatives to transplantation, increasing development of portable and transport-compatible artificial lung units for emergency care settings, expanding use of membrane-based artificial lung technologies for efficient gas exchange and long-term support.
The rising prevalence of respiratory diseases is expected to drive growth in the artificial lung market in the coming years. Factors such as increasing air pollution, climate change, and lifestyle changes have contributed to a growing burden of respiratory conditions on public health. Artificial lungs are employed to support or replace impaired lung function by providing oxygenation and removing carbon dioxide from the blood. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, approximately 8.5 million Australians, or 34% of the population, were estimated to have chronic respiratory conditions. This includes an estimated 2.8 million people (11% of the population) living with asthma and 638,000 people (2.5% of the population) living with chronic obstructive pulmonary disease (COPD). As a result, the growing prevalence of respiratory diseases is propelling the artificial lung market forward.
Major companies operating in the artificial lung market are focusing on developing advanced solutions, such as portable pneumatic ECMO systems, to extend extracorporeal life support beyond the ICU and facilitate rapid patient transport and field deployment. Portable pneumatic ECMO systems use oxygen-supply-driven pumps and integrated gas management to provide extracorporeal oxygenation and circulatory support without dependence on external electric power or heavy motorized components. For instance, in May 2024, Hemovent GmbH, a Germany-based medical device company, announced that MOBYBOX, the world’s first integrated portable pneumatic ECMO system, completed its initial commercial applications in Europe. MOBYBOX weighs approximately 2.5 kg, operates solely on oxygen supply without a battery or motor, incorporates Bionique Flow Technology for gentler blood handling and enhanced gas exchange, and has obtained Medical Device Regulation certification for its initial markets.
In August 2024, Getinge AB, a Sweden-based medical technology company, acquired Paragonix Technologies for approximately US$477 million. This acquisition is intended to expand Getinge’s organ preservation and transplant logistics portfolio by integrating Paragonix’s advanced organ transport and storage systems, thereby improving transplant outcomes and strengthening Getinge’s position in cardiac and thoracic transplant workflows. Paragonix Technologies is a US-based company specializing in organ preservation and transport solutions for cardiac and thoracic transplantation.
Major companies operating in the artificial lung market are Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, Fresenius Medical Care AG & Co KGaA, ALung Technologies Inc, Xenios AG, Eurosets S.r.l, Nipro Corporation, Braile Biomédica, Hemovent GmbH, MC3 Cardiopulmonary Inc, Abbott Laboratories, Spectrum Medical Ltd, B Braun Melsungen AG, SB‑Kawasumi Laboratories Inc, Senko Medical Instrument Mfg Co Ltd, CARMAT, Technowood International Pte Ltd, Elite Lifecare, Cytosorbents Corporation.
North America was the largest region in the artificial lung market in 2025. The regions covered in the artificial lung market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial lung market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the artificial lung market by increasing the cost of imported precision components, membranes, pumps, and control electronics used in heart-lung machines and membrane artificial lung systems, thereby raising overall production and procurement costs for hospitals and emergency care facilities. The most affected segments include membrane artificial lung devices and portable roller pump systems, particularly in regions dependent on international sourcing such as Asia-Pacific and Europe. At the same time, tariffs are encouraging near-shore manufacturing, regional assembly, and supplier diversification, which may support innovation and strengthen supply resilience in the long term across artificial lung product segments.
The artificial lung market research report is one of a series of new reports that provides artificial lung market statistics, including artificial lung industry global market size, regional shares, competitors with a artificial lung market share, detailed artificial lung market segments, market trends and opportunities, and any further data you may need to thrive in the artificial lung industry. This artificial lung market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An artificial lung is a medical device created to assume the function of natural lungs by supplying oxygen to the blood and eliminating carbon dioxide. It is commonly employed in patients experiencing severe respiratory failure or during surgeries where temporary cessation of heart and lung function is necessary. This technology aims to support or replace lung function, facilitating patient survival and recovery from critical conditions.
The primary types of artificial lungs include single roller pump heart-lung machines, double roller pump heart-lung machines, bubble artificial lungs, and membrane artificial lungs. A single roller pump heart-lung machine operates using a single roller pump to circulate blood through an artificial lung and back into the patient during cardiopulmonary bypass surgery. These machines are utilized in cardiac surgery, lung transplants, acute respiratory failure treatments, and other medical procedures, catering to diverse end users such as hospitals, emergency centers, and healthcare facilities.
The artificial lung market consists of sales of extracorporeal membrane oxygenation (ECMO), intravenous membrane oxygenators (IVOX), bioartificial lungs, and microfluidic artificial lungs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The artificial lung market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for critical care life-support devices, growing focus on portable and compact artificial lung systems, rising investment in advanced oxygenation membrane materials, expansion of applications in emergency and trauma care, increasing adoption of minimally invasive extracorporeal support solutions. Major trends in the forecast period include increasing demand for artificial lung systems in severe respiratory failure and critical care management, rising adoption of extracorporeal support devices in complex cardiac and lung transplant surgeries, growing preference for minimally invasive and temporary lung support alternatives to transplantation, increasing development of portable and transport-compatible artificial lung units for emergency care settings, expanding use of membrane-based artificial lung technologies for efficient gas exchange and long-term support.
The rising prevalence of respiratory diseases is expected to drive growth in the artificial lung market in the coming years. Factors such as increasing air pollution, climate change, and lifestyle changes have contributed to a growing burden of respiratory conditions on public health. Artificial lungs are employed to support or replace impaired lung function by providing oxygenation and removing carbon dioxide from the blood. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, approximately 8.5 million Australians, or 34% of the population, were estimated to have chronic respiratory conditions. This includes an estimated 2.8 million people (11% of the population) living with asthma and 638,000 people (2.5% of the population) living with chronic obstructive pulmonary disease (COPD). As a result, the growing prevalence of respiratory diseases is propelling the artificial lung market forward.
Major companies operating in the artificial lung market are focusing on developing advanced solutions, such as portable pneumatic ECMO systems, to extend extracorporeal life support beyond the ICU and facilitate rapid patient transport and field deployment. Portable pneumatic ECMO systems use oxygen-supply-driven pumps and integrated gas management to provide extracorporeal oxygenation and circulatory support without dependence on external electric power or heavy motorized components. For instance, in May 2024, Hemovent GmbH, a Germany-based medical device company, announced that MOBYBOX, the world’s first integrated portable pneumatic ECMO system, completed its initial commercial applications in Europe. MOBYBOX weighs approximately 2.5 kg, operates solely on oxygen supply without a battery or motor, incorporates Bionique Flow Technology for gentler blood handling and enhanced gas exchange, and has obtained Medical Device Regulation certification for its initial markets.
In August 2024, Getinge AB, a Sweden-based medical technology company, acquired Paragonix Technologies for approximately US$477 million. This acquisition is intended to expand Getinge’s organ preservation and transplant logistics portfolio by integrating Paragonix’s advanced organ transport and storage systems, thereby improving transplant outcomes and strengthening Getinge’s position in cardiac and thoracic transplant workflows. Paragonix Technologies is a US-based company specializing in organ preservation and transport solutions for cardiac and thoracic transplantation.
Major companies operating in the artificial lung market are Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, Fresenius Medical Care AG & Co KGaA, ALung Technologies Inc, Xenios AG, Eurosets S.r.l, Nipro Corporation, Braile Biomédica, Hemovent GmbH, MC3 Cardiopulmonary Inc, Abbott Laboratories, Spectrum Medical Ltd, B Braun Melsungen AG, SB‑Kawasumi Laboratories Inc, Senko Medical Instrument Mfg Co Ltd, CARMAT, Technowood International Pte Ltd, Elite Lifecare, Cytosorbents Corporation.
North America was the largest region in the artificial lung market in 2025. The regions covered in the artificial lung market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial lung market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the artificial lung market by increasing the cost of imported precision components, membranes, pumps, and control electronics used in heart-lung machines and membrane artificial lung systems, thereby raising overall production and procurement costs for hospitals and emergency care facilities. The most affected segments include membrane artificial lung devices and portable roller pump systems, particularly in regions dependent on international sourcing such as Asia-Pacific and Europe. At the same time, tariffs are encouraging near-shore manufacturing, regional assembly, and supplier diversification, which may support innovation and strengthen supply resilience in the long term across artificial lung product segments.
The artificial lung market research report is one of a series of new reports that provides artificial lung market statistics, including artificial lung industry global market size, regional shares, competitors with a artificial lung market share, detailed artificial lung market segments, market trends and opportunities, and any further data you may need to thrive in the artificial lung industry. This artificial lung market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An artificial lung is a medical device created to assume the function of natural lungs by supplying oxygen to the blood and eliminating carbon dioxide. It is commonly employed in patients experiencing severe respiratory failure or during surgeries where temporary cessation of heart and lung function is necessary. This technology aims to support or replace lung function, facilitating patient survival and recovery from critical conditions.
The primary types of artificial lungs include single roller pump heart-lung machines, double roller pump heart-lung machines, bubble artificial lungs, and membrane artificial lungs. A single roller pump heart-lung machine operates using a single roller pump to circulate blood through an artificial lung and back into the patient during cardiopulmonary bypass surgery. These machines are utilized in cardiac surgery, lung transplants, acute respiratory failure treatments, and other medical procedures, catering to diverse end users such as hospitals, emergency centers, and healthcare facilities.
The artificial lung market consists of sales of extracorporeal membrane oxygenation (ECMO), intravenous membrane oxygenators (IVOX), bioartificial lungs, and microfluidic artificial lungs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Artificial Lung Market Characteristics
3. Artificial Lung Market Supply Chain Analysis
4. Global Artificial Lung Market Trends and Strategies
5. Artificial Lung Market Analysis of End Use Industries
7. Global Artificial Lung Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Artificial Lung Total Addressable Market (TAM) Analysis for the Market
9. Artificial Lung Market Segmentation
10. Artificial Lung Market Regional and Country Analysis
11. Asia-Pacific Artificial Lung Market
12. China Artificial Lung Market
13. India Artificial Lung Market
14. Japan Artificial Lung Market
15. Australia Artificial Lung Market
16. Indonesia Artificial Lung Market
17. South Korea Artificial Lung Market
18. Taiwan Artificial Lung Market
19. South East Asia Artificial Lung Market
20. Western Europe Artificial Lung Market
21. UK Artificial Lung Market
22. Germany Artificial Lung Market
23. France Artificial Lung Market
24. Italy Artificial Lung Market
25. Spain Artificial Lung Market
26. Eastern Europe Artificial Lung Market
27. Russia Artificial Lung Market
28. North America Artificial Lung Market
29. USA Artificial Lung Market
30. Canada Artificial Lung Market
31. South America Artificial Lung Market
32. Brazil Artificial Lung Market
33. Middle East Artificial Lung Market
34. Africa Artificial Lung Market
36. Artificial Lung Market Competitive Landscape and Company Profiles
37. Artificial Lung Market Other Major and Innovative Companies
40. Artificial Lung Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Artificial Lung Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses artificial lung market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for artificial lung? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial lung market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Single Roller Pump Heart Lung Machines; Double Roller Pump Heart Lungs Machines; Bubble Artificial Lung; Membrane Artificial Lung2) By Application: Cardiac Surgery; Lung Transplant Operation; Acute Respiratory Failure Treatment; Other Applications
3) By End-Users: Hospital; Emergency Center; Other End-users
Subsegments:
1) By Single Roller Pump Heart Lung Machines: Portable Single Roller Pump Heart Lung Machines; Stationary Single Roller Pump Heart Lung Machines2) By Double Roller Pump Heart Lung Machines: Portable Double Roller Pump Heart Lung Machines; Stationary Double Roller Pump Heart Lung Machines
3) By Bubble Artificial Lung: Disposable Bubble Artificial Lung; Reusable Bubble Artificial Lung
4) By Membrane Artificial Lung: Oxygenator Membrane Artificial Lung; Carbon Dioxide Removal Membrane Artificial Lung
Companies Mentioned: Getinge AB; Medtronic plc; LivaNova PLC; Terumo Corporation; Fresenius Medical Care AG & Co KGaA; ALung Technologies Inc; Xenios AG; Eurosets S.r.l; Nipro Corporation; Braile Biomédica; Hemovent GmbH; MC3 Cardiopulmonary Inc; Abbott Laboratories; Spectrum Medical Ltd; B Braun Melsungen AG; SB‑Kawasumi Laboratories Inc; Senko Medical Instrument Mfg Co Ltd; CARMAT; Technowood International Pte Ltd; Elite Lifecare; Cytosorbents Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Artificial Lung market report include:- Getinge AB
- Medtronic plc
- LivaNova PLC
- Terumo Corporation
- Fresenius Medical Care AG & Co KGaA
- ALung Technologies Inc
- Xenios AG
- Eurosets S.r.l
- Nipro Corporation
- Braile Biomédica
- Hemovent GmbH
- MC3 Cardiopulmonary Inc
- Abbott Laboratories
- Spectrum Medical Ltd
- B Braun Melsungen AG
- SB‑Kawasumi Laboratories Inc
- Senko Medical Instrument Mfg Co Ltd
- CARMAT
- Technowood International Pte Ltd
- Elite Lifecare
- Cytosorbents Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.88 Billion |
| Forecasted Market Value ( USD | $ 4.27 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
